COPENHAGEN, APRIL 07, 2016 – AntibioTx welcomes the collaboration with Professor Mylonakis and foresees it as a very important step towards extracting the compound class potentials.
Professor Mylonakis is an expert in molecular biology, biostatistics, microbial and pathogenesis, which he often combines with a pragmatic problem-solving approach such as developing methods and strategies against antimicrobial resistance.
Professor Mylonakis is currently chief of the Infectious Diseases Division and Dean’s Professor of Medicine at the Warren Alpert Medical School of Brown. He has published more than 200 peer-reviewed scientific articles edited five books and has been on the editorial board of 10 scientific and peer-reviewed journals.
Mylonakis has received several awards for his research, counting awards from the American Society for Microbiology and the Infectious Disease Society of America.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.